Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Zogenix Inc. ZGNX

Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes Fintepla, dose fenfluramine for the treatment of Dravet syndrome, and MT-1621 for a rare, life-threatening mitochondrial depletion disease, thymidine kinase 2 deficiency (TK2d). It operates as a single operating segment engaged in the research, development, and commercialization of pharmaceutical products.


NDAQ:ZGNX - Post by User

Bullboard Posts
Post by traderguy5000on Apr 30, 2016 4:39pm
212 Views
Post# 24829253

Stockhouse Problems

Stockhouse ProblemsLooks like we are once again having trouble with Stockhouse. Somehow, SEI has been put in the healthcare category, and our posts are going here, rather that the SEI board in energy. Hopefully, at some point, the SEI board will be back in order.
Bullboard Posts